Synbiotic for Prevention of SARS-Cov2 Infection in High Risk Hospital Staffs: A Randomized Controlled Trial

Ahanchian, Hamid; Ranjbar, Alireza; Reihani, Hamidreza; Yazdi, Arash Peivandi; Jafari, Seyed Ali; Kiani, Mohammad Ali; Tafrishi, Rana; Haghi, Nasrinsadat Motevalli; Moazzen, Nasrin; Khalshour, Ali; Mirzaei, Fatemeh; Shaye, Zahra Abbasi; Ebrahimi, Sadegh; Kianifar, Hamidreza

doi:10.4236/ojn.2021.115025

Cited by 6 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three separate large randomized controlled trials compared similar synbiotic supplements (containing 3 to 5 strains of Lactobacillus plantarum, Lactobacillus rhamnosus , and Bifidobacterium lactis , lactoferrin and prebiotics such as either FOS (short-chain fructooligosaccharides) or GOS (galactooligosaccharides)) to placebo, and all three of these trials showed reductions in the incidence, duration, and severity of RTI with the synbiotic ( 276 ). It was also proposed that this synbiotic could reduce SARS-Cov2 infection in high-risk medical staff working in COVID-19 hospital wards ( 277 ).…”

Section: Pro and Synbioticsmentioning

confidence: 99%

Ingestion, Immunity, and Infection: Nutrition and Viral Respiratory Tract Infections

et al. 2022

View full text Add to dashboard Cite

Respiratory infections place a heavy burden on the health care system, particularly in the winter months. Individuals with a vulnerable immune system, such as very young children and the elderly, and those with an immune deficiency, are at increased risk of contracting a respiratory infection. Most respiratory infections are relatively mild and affect the upper respiratory tract only, but other infections can be more serious. These can lead to pneumonia and be life-threatening in vulnerable groups. Rather than focus entirely on treating the symptoms of infectious disease, optimizing immune responsiveness to the pathogens causing these infections may help steer towards a more favorable outcome. Nutrition may have a role in such prevention through different immune supporting mechanisms. Nutrition contributes to the normal functioning of the immune system, with various nutrients acting as energy sources and building blocks during the immune response. Many micronutrients (vitamins and minerals) act as regulators of molecular responses of immune cells to infection. It is well described that chronic undernutrition as well as specific micronutrient deficiencies impair many aspects of the immune response and make individuals more susceptible to infectious diseases, especially in the respiratory and gastrointestinal tracts. In addition, other dietary components such as proteins, pre-, pro- and synbiotics, and also animal- and plant-derived bioactive components can further support the immune system. Both the innate and adaptive defense systems contribute to active antiviral respiratory tract immunity. The initial response to viral airway infections is through recognition by the innate immune system of viral components leading to activation of adaptive immune cells in the form of cytotoxic T cells, the production of neutralizing antibodies and the induction of memory T and B cell responses. The aim of this review is to describe the effects of a range different dietary components on anti-infective innate as well as adaptive immune responses and to propose mechanisms by which they may interact with the immune system in the respiratory tract.

show abstract

Section: Pro and Synbioticsmentioning

confidence: 99%

Ingestion, Immunity, and Infection: Nutrition and Viral Respiratory Tract Infections

et al. 2022

View full text Add to dashboard Cite

show abstract

“…We included 18 studies (11 RCTs and 7 observational studies) in our review (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35). The details of the screening process are presented in Figure 1.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis

Sohail,

Cheema,

Mithani

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

BackgroundAlthough numerous modalities are currently in use for the treatment and prophylaxis of COVID-19, probiotics are a cost-effective alternative that could be used in diverse clinical settings. Hence, we conducted a meta-analysis to investigate the role of probiotics in preventing and treating COVID-19 infection.MethodsWe searched several databases from inception to 30 May 2023 for all randomized controlled trials (RCTs) and comparative observational studies that evaluated probiotics (irrespective of the regimen) for the treatment or prevention of COVID-19. We conducted our meta-analysis using RevMan 5.4 with risk ratio (RR) and mean difference (MD) as the effect measures.ResultsA total of 18 studies (11 RCTs and 7 observational studies) were included in our review. Probiotics reduced the risk of mortality (RR 0.40; 95% CI: 0.25–0.65, I2 = 0%). Probiotics also decreased the length of hospital stay, rate of no recovery, and time to recovery. However, probiotics had no effect on the rates of ICU admission. When used prophylactically, probiotics did not decrease the incidence of COVID-19 cases (RR 0.65; 95% CI: 0.37–1.12; I2 = 66%). The results for all outcomes were consistent across the subgroups of RCTs and observational studies (P for interaction >0.05).ConclusionThe results of this meta-analysis support the use of probiotics as an adjunct treatment for reducing the risk of mortality or improving other clinical outcomes in patients with COVID-19. However, probiotics are not useful as a prophylactic measure against COVID-19. Large-scale RCTs are still warranted for determining the most efficacious and safe probiotic strains.Systematic Review RegistrationPROSPERO (CRD42023390275: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=390275).

show abstract

“…These microorganisms can be incorporated into various products, including yogurt and pharmaceuticals, and have been studied extensively for their ability to prevent infectious diseases and modulate immune function [11]. Clinical studies, including randomized controlled trials, have demonstrated the efficacy of probiotics in mitigating COVID-19 symptoms and improving immune responses [16] [17]. Probiotics have shown comparable or even superior outcomes compared to traditional treatments in some cases.…”

Section: Introductionmentioning

confidence: 99%

Antiviral Activity of Probiotics in the Prophylaxis and Treatment of Respiratory Infections Associated with Coronavirus (COVID-19): A Meta-Analysis of Randomized Controlled Trials

Mokadem,

Naimi,

Alami

2024

Preprint

View full text Add to dashboard Cite

Introduction: Probiotics, living microorganisms administered in sufficient quantities, exert beneficial effects on host health. Given the high prevalence of SARS-CoV-2, recent studies suggest potential positive impacts of probiotics on COVID-19 patients. Methods: A predetermined search strategy encompassing seven databases, NCBI, PubMed, Science Direct, Springer Link, Embase, CNKI, and Cochrane Library Databases, was implemented. Human RCTs were scrutinized independently for data extraction, quality and risk of bias assessment, and statistical analysis. Pooled data, employing the random-effects model, are expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs). Assessments of the p value and heterogeneity (I²) were conducted and quantified. Results: Five studies comprising 282 out of 375 participants were included. The meta-analysis revealed effects on various parameters: CRP level (SMD=0.26 MG/L, 95% CI [0.10, 0.43], p= 0.002, (I²=67%, p=0.03); BMI (SMD=0.28 KG/m², 95% CI [0.07, 0.50], p= 0.01, (I²=67%, p=0.40); T-cell count (SMD=0.09 G/L, 95% CI [-0.07, 0.26], p= 0.26, (I²=0%, p=0.73); Albumin level (SMD=0.28 G/DL, 95% CI [0.04, 0.52], p= 0.02, (I²=7%, p=0.34); IL-6 level (SMD=0.67, 95% CI [0.45, 0.90], p= 0.00001, (I²=94%, p=0.0001)); and LDH level (SMD=0.12 mmol/L, 95% CI [-0.05, 0.30], p= 0.17 Conclusion: This meta-analysis suggested that probiotics had significant positive effects on various measures for treating COVID-19.

show abstract

Synbiotic for Prevention of SARS-Cov2 Infection in High Risk Hospital Staffs: A Randomized Controlled Trial

Cited by 6 publications

References 26 publications

Ingestion, Immunity, and Infection: Nutrition and Viral Respiratory Tract Infections

Ingestion, Immunity, and Infection: Nutrition and Viral Respiratory Tract Infections

Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis

Antiviral Activity of Probiotics in the Prophylaxis and Treatment of Respiratory Infections Associated with Coronavirus (COVID-19): A Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About